
Solvency II: capital charge for PE could be lower than expected
The capital charge associated with private equity in the Solvency II directive could ultimately be lowered from the current 49% to 39%, unquote" understands.
Latest News
Alta Life Sciences invests in Inbiomotion
Existing investors including Institut Català de Finances also take part in the financing
Korys, FPIM et al. in €12m extended series-B for Remynd
Biotech company initially raised €12m in December 2018
Eurazeo raises €2.8bn in 2020
Amount includes the capital raised by Eurazeo Growth III, which has now collected more than €500m
ICG hires Bridge Valley's life sciences investment team
Allan Marchington, who will become head of ICG life sciences, says the team has a strong pipeline
Back to Top